← Leaderboards
Jonathan K Watts
Univ Of Massachusetts Med Sch Worcester
$5,302,344
Attributed
$16,677,122
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.2M · FY2018–25$10M$7.5M$5M$2.5M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,677,122 · 4
By mechanism
U01$6,580,415 · 1
R01$4,532,255 · 1
UH3$3,091,036 · 1
UG3$2,473,416 · 1
Top collaborators
- Robert H Brown7 shared
- Erik J Sontheimer7 shared
- Scot A Wolfe7 shared
- Anastasia Khvorova6 shared
- Fen-Biao Gao1 shared
Most similar at Univ Of Massachusetts Med Sch Worcester
Same institution · by research overlap
- Fen-Biao Gao$25,894,740
- Daryl A Bosco$10,705,670
- Francesca Massi$6,479,357
- Eric Wayne Danielson$172,166
- Maire F Osborn$164,204
Others in their field
Other Emerging Leaders on “Specificity”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$225,117,487
- Kevin Urdahl · Seattle Children'S Hospital$79,298,344
- Yunda Huang · Fred Hutchinson Cancer Center$71,543,089
Research focus
SpecificityTechnologyGenesOligonucleotidesIn VivoClinical DevelopmentAntisense OligonucleotidesUptakeAnimal ModelChemistryNucleaseModificationDigestionPropertyBaseNeuraxisSafetySmall Interfering RnaToxic EffectMouse ModelBiodistributionDisease PhenotypeEffective TherapyMediating
Grant awards (14)
Precision Editing of Granulin Mutations that Cause Frontotemporal Dementia$6,580,415
U01 · FY2025 · NS
Multi-Targeting Oligonucleotide Therapeutics for Familial and Sporadic Amyotrophic Lateral Sclerosis$665,737
R01 · FY2025 · NS · contact PI
Multi-Targeting Oligonucleotide Therapeutics for Familial and Sporadic Amyotrophic Lateral Sclerosis$665,737
R01 · FY2024 · NS · contact PI
Next-generation antisense therapeutics for ALS and frontotemporal dementia$635,090
R01 · FY2023 · NS · contact PI
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors$1,370,507
UH3 · FY2022 · TR
Next-generation antisense therapeutics for ALS and frontotemporal dementia$635,090
R01 · FY2022 · NS · contact PI
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors$333,834
UH3 · FY2022 · TR
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors$1,386,695
UH3 · FY2021 · TR
Next-generation antisense therapeutics for ALS and frontotemporal dementia$635,090
R01 · FY2021 · NS · contact PI
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors$819,031
UG3 · FY2020 · TR
Next-generation antisense therapeutics for ALS and frontotemporal dementia$635,090
R01 · FY2020 · NS · contact PI
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors$828,360
UG3 · FY2019 · TR
Next-generation antisense therapeutics for ALS and frontotemporal dementia$660,421
R01 · FY2019 · NS · contact PI
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors$826,025
UG3 · FY2018 · TR